Evidence map›Paper›PMID 37058168›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

Radioligand therapies in cancer: mapping the educational landscape in Europe.

Valentina Bugani, Luca Battistelli, Maddalena Sansovini, Manuela Monti, Giovanni Paganelli, Ignasi Gich, Albert Flotats, Paola Anna Erba, Jean-Yves Blay, Christian la Fougère and 8 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Valentina BuganiResearch, Technology Transfer and Training Office, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, Meldola, FC, 47014, Italy. valentina.bugani@irst.emr.it.
Luca BattistelliResearch, Technology Transfer and Training Office, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, Meldola, FC, 47014, Italy.
Maddalena SansoviniNuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), "Dino Amadori", Meldola, Italy.
Manuela MontiUnit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Giovanni PaganelliNuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), "Dino Amadori", Meldola, Italy.
Ignasi GichDepartment of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Albert FlotatsDepartment of Nuclear Medicine, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Paola Anna ErbaDepartment of Translational Research and New Technology in Medicine and Surgery, Regional Center of Nuclear Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Jean-Yves BlayDepartment of Cancer Medicine, "Léon Bérard" Cancer Center, Lyon, France.
Christian la FougèreDepartment of Nuclear Medicine and Clinical Molecular Imaging, University Hospital of Tuebingen, Tuebingen, Germany.
Hendrik Van PoppelDepartment of Urology, KU University Hospitals of Leuven, Louvain, Belgium.
Andreas CharalambousDepartment of Nursing, Cyprus University of Technology, Limassol, Cyprus.
Ken HerrmannDepartment of Nuclear Medicine, University Hospital of Essen, Essen, Germany.
Alessandro GiordanoUnit of Nuclear Medicine, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Tamás GyörkeDepartment of Nuclear Medicine, Medical Imaging Center, "I. Semmelweis" University, Budapest, Hungary.
Christophe DerooseNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU University Hospitals of Leuven, Louvain, Belgium.
Federica MatteucciNuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), "Dino Amadori", Meldola, Italy.
Ignasi CarrióDepartment of Nuclear Medicine, Autonomous University of Barcelona (UAB), Barcelona, Spain.

Funding

European Commission, ERASMUS+ Program (KA220-HED) 2021-1-BE02-KA220-HED-000032124
6 · The paper itself

Abstract

aimWe performed a systematic survey to assess the existing gaps in Europe in multidisciplinary education for integration of radioligand therapy (RLT) into cancer care and to obtain detailed information on the current limitations and key contents relevant.

methodsA high-quality questionnaire, with emphasis on survey scales, formulation, and validity of the different items, was designed. An expert validation process was undertaken. The survey was circulated among medical specialties involved in cancer treatment, universities, and nursing organizations. Questionnaires (156) were distributed, and 95 responses received.

resultsSevety-eight percent of medical societies indicated that training in RLT was very important and 12% important. Eighty-eight percent indicated that their specialty training program included RLT. Twenty-six percent were satisfied with the existing structure of training in RLTs. Ninety-four percent indicated that the existing training is based on theory and hands-on experience. Main identified limitations were lack of centers ready to train and of personnel available for teaching. Sixty-five percent indicated that national programs could be expanded. Fifty percent of consulted universities indicated partial or scarce presence of RLT contents in their teaching programs. In 26% of the cases, the students do not have the chance to visit a RLT facility. A large majority of the universities are interested in further expansion of RLT contents in their curriculums. Nursing organizations almost never (44.4%) or occasionally (33.3%) include RLT contents in the education of nurses and technologists. Hands-on experience is almost never (38%) and sometimes (38%) offered. However, 67% of centers indicated high interest in expanding RLT contents.

conclusionCenters involved recognize the importance of the training and indicate a need for inclusion of additional clinical content, imaging analysis, and interpretation as well as extended hands-on training. A concerted effort to adapt current programs and a shift towards multidisciplinary training programs is necessary for proper education in RLT in Europe.

Indexed as

NeoplasmsEuropeHumansSurveys and QuestionnairesCancerEducationRadioligand therapyRLTSurveyTraining’s gap

Identifiers

PMID37058168
PMCPMC10102677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.